MO
Morepen Laboratories Limited
MOREPENLAB.NS · NSE
₹115.72 +0.38% (+₹0.44)
1M +28.90%
Market Cap ₹63.4B
P/E Ratio 45.12x
Div. Yield -
ROE 11.50%
Bulios Fair Price
₹92.81
19.8% downside
Current Price
₹115.72
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MOREPENLAB.NS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
18 /100
Expensive PEG 2.36x
P/S 3.25x
P/B 5.08x
Growth
52 /100
Stable Rev. growth 5.88%
Book val. growth 25.96%
EPS growth 3.93%
Profitability
33 /100
Weak Net margin 7.20%
Op. margin 7.60%
FCF margin 1.27%
Quality
53 /100
Average ROE 11.50%
ROA N/A
Asset turnover N/A
Debt
99 /100
Low Int. coverage 11.09x
Net debt/EBITDA 0.00x
Debt/Equity 0.00x
Stability
63 /100
Moderate Rev. volatility 14.08%
EPS volatility 103.42%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MOREPENLAB.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sushil Suri
Employees
2,152
Headquarters
Gurugram
Upcoming events
18 SEP
Ex-Dividend
Ex-dividend date
26 OCT
Dividend Payment
Payment date